Literature DB >> 1699198

Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation.

F D Kury1, C Schneeberger, G Sliutz, E Kubista, H Salzer, M Medl, S Leodolter, H Swoboda, R Zeillinger, J Spona.   

Abstract

A rapid, simple and non-toxic procedure for the simultaneous isolation of DNA and RNA from tumor tissue and cells grown in vitro is described. Guanidinium isothiocyanate was used for homogenization of tumor tissue and for cell lysis. Separation of proteins, DNA and RNA was carried out by isopycnic centrifugation in cesium trifluoroacetate. DNA was further purified by salting out residual protein. Nucleic acids prepared by this method from 47 primary human carcinomas and 17 human cell lines were analysed for amplification and expression of the HER-2/neu proto-oncogene. 2- to 10-fold amplification of HER-2/neu was noted in 7/22 mammary carcinomas (32%) and in 4/14 ovarian carcinomas (28%). No amplification of the proto-oncogene was found in 4 laryngeal carcinomas, 1 pharyngeal carcinoma, 2 retrolingual carcinomas, 3 gastric carcinomas and 1 kidney carcinoma. HER-2/neu overexpression was observed in 6/22 of mammary carcinomas (27%) and 7/14 of ovarian carcinomas (50%). No overexpression was found in all other carcinomas studied. Concordance between amplification and overexpression was noted in 3 mammary and 4 ovarian carcinomas, respectively. 3 mammary and 3 ovarian carcinomas showed overexpression without amplification. 5 human mammary carcinoma cell lines showed both amplification and overexpression of HER-2/neu. In two mammary carcinoma cell lines (MDA MB-453 and ZR 75-1) overexpression was noted without amplification of the proto-oncogene. These data combine to suggest that mechanisms other than gene amplification may also lead to overexpression of the HER-2/neu protooncogene in cancer cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699198

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Modified salting-out method for DNA isolation from newborn cord blood nucleated cells.

Authors:  N I Noguera; C E Tallano; I M Bragós; A C Milani
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Amplification of Guthrie card DNA: effect of guanidine thiocyanate on binding of natural whole blood PCR inhibitors.

Authors:  G S Makowski; E L Davis; S M Hopfer
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

3.  Simultaneous expression of nitric oxide synthase and estrogen receptor in human breast cancer cell lines.

Authors:  R Zeillinger; E Tantscher; C Schneeberger; W Tschugguel; S Eder; G Sliutz; J C Huber
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR.

Authors:  G Sliutz; H Eder; H Koelbl; C Tempfer; L Auerbach; C Schneeberger; C Kainz; R Zeillinger
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients.

Authors:  Dan Tong; Georg Heinze; Dietmar Pils; Andrea Wolf; Christian F Singer; Nicole Concin; Gerda Hofstetter; Ingrid Schiebel; Margaretha Rudas; Robert Zeillinger
Journal:  BMC Cancer       Date:  2010-12-15       Impact factor: 4.430

6.  The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer.

Authors:  D Stein; J Wu; S A Fuqua; C Roonprapunt; V Yajnik; P D'Eustachio; J J Moskow; A M Buchberg; C K Osborne; B Margolis
Journal:  EMBO J       Date:  1994-03-15       Impact factor: 11.598

7.  A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines.

Authors:  D P Hollywood; H C Hurst
Journal:  EMBO J       Date:  1993-06       Impact factor: 11.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.